New research led by investigators at the Seaver Autism Center for Research and Treatment at Mount Sinai suggests that Phelan-McDermid syndrome (PMS) is substantially more common than historical medical estimates have indicated. Published in the journal Autism Research, the comprehensive study establishes a new prevalence rate of approximately 1 in 7,300 individuals. This finding represents a significant recalibration of the diagnostic landscape, suggesting that more than 45,000 people across the United States may be living with the genetic condition, many of whom remain undiagnosed.
Understanding the Genetic Basis of PMS
Phelan-McDermid syndrome, also known as 22q13.3 deletion syndrome, is a rare genetic disorder characterized by the deletion or mutation of the SHANK3 gene located on the distal end of chromosome 22. This specific gene is critical for the development of synaptic connections in the brain. Because SHANK3 facilitates the communication between neurons, its absence or dysfunction results in a wide array of neurodevelopmental, intellectual, and physical challenges.
Clinical manifestations of the syndrome are heterogeneous. While many individuals exhibit global developmental delays, hypotonia, and absent or delayed speech, the condition is also closely linked to the autism spectrum. Research indicates that as many as one percent of all individuals diagnosed with autism spectrum disorder (ASD) possess genetic variations related to the SHANK3 gene. The broad clinical presentation of PMS—which can include gastrointestinal issues, epilepsy, and sensory processing differences—often complicates the diagnostic process, leading many patients to remain in the healthcare system without a specific genetic etiology for their symptoms.
Methodological Rigor: Analyzing a Massive Genetic Dataset
To arrive at the revised prevalence estimate, the Mount Sinai research team undertook an exhaustive analysis of genetic data. The study spanned a massive cohort of nearly 180,000 individuals with autism who had previously undergone some form of genetic screening. By integrating information from ten diverse sources—including major diagnostic laboratories like GeneDx, Labcorp, and Ambry Genetics, alongside the SPARK research study and the Autism Sequencing Consortium—the team created one of the most robust datasets for rare disease prevalence ever assembled.
The researchers employed a multi-step analytical approach to account for the "diagnostic gap." This process involved adjusting for known limitations in standard genetic testing panels, which often do not cover the entire SHANK3 sequence, as well as accounting for individuals who exhibit the clinical symptoms of PMS but do not strictly meet the diagnostic criteria for autism. After weighting these variables, the team concluded that a prevalence rate of 13.7 cases per 100,000 individuals provides a more accurate reflection of the population than the anecdotal or outdated figures previously used by clinicians.
Chronology of Diagnostic Evolution
The history of PMS research is relatively young, paralleling the rapid advancements in genomic sequencing technology.
- 1988: The first clinical descriptions of the syndrome were reported by Dr. Katy Phelan, who identified the link between 22q13 deletions and neurodevelopmental delays.
- Late 1990s and 2000s: The identification of SHANK3 as the primary driver of the phenotype allowed for more targeted molecular diagnostics.
- 2010s: The rise of Whole Exome Sequencing (WES) began to uncover a higher number of SHANK3 mutations in patients previously classified under broader autism diagnoses.
- 2024: The current Mount Sinai study marks a shift toward epidemiological precision, moving away from "rare disease" estimates based on small patient registries and toward data-driven population statistics.
The Diagnostic Barrier: Why Patients Remain Undiagnosed
The disparity between the estimated 45,000 cases in the U.S. and the number of currently diagnosed individuals highlights systemic issues within the healthcare framework. Tess Levy, MSc, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and the study’s first author, notes that the obstacles are threefold: lack of access to testing, economic barriers, and the limitations of current diagnostic panels.
"The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," Levy explained. Even when testing is ordered, she points out, it may be insufficient. Many insurance providers limit coverage for comprehensive genomic testing, or clinicians may order chromosomal microarrays that fail to detect smaller, intragenic mutations within the SHANK3 gene. Consequently, many families are left without an answer, which prevents them from accessing specialized care or participating in clinical trials.
The Imperative of Genetic Literacy
The research team is advocating for a paradigm shift in how pediatricians and neurologists approach autism diagnoses. Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center and senior author of the study, emphasizes that the identification of a genetic cause is not merely an academic exercise—it is the foundation for future medical intervention.
"We recommend that every child with autism undergo genetic testing, because knowledge is power," Dr. Buxbaum stated. He posits that the next five years will be transformative for the field, as genetic discoveries move from the laboratory bench to the patient bedside. By identifying the specific molecular pathway involved in a patient’s condition, researchers can design clinical trials that target the biology of the disorder rather than just managing symptoms.
Clinical Implications: From Diagnosis to Treatment
The publication of these findings coincides with a pivotal moment in the therapeutic pipeline for PMS. Several pharmaceutical firms and research institutions are currently advancing precision medicine approaches intended to compensate for SHANK3 insufficiency.
For the families involved, a genetic diagnosis functions as a gateway. It provides entry into patient advocacy networks like CureSHANK, allows for enrollment in specialized registries, and qualifies patients for clinical trials that are increasingly focused on disease-modifying therapies. Without a diagnosis, these individuals are effectively invisible to the drug development pipeline.
Rachel Groth, PhD, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, which supported the study, underscored the ethical necessity of this research. "Patients cannot benefit from these advances if they never receive a diagnosis," she said. The collaboration between Neuren, the Seaver Autism Center, and CureSHANK serves as a model for how industry and academic partnerships can address the diagnostic void in rare diseases.
Broader Impact and Future Directions
The ripple effects of this study extend beyond Phelan-McDermid syndrome. By demonstrating that the prevalence of a specific genetic condition is significantly higher than previously suspected, the research validates the concerns of patient advocates who have long argued that rare diseases are being undercounted.
Geraldine Bliss, Board Chair of CureSHANK, welcomed the study as a vindication of the advocacy community’s long-standing observations. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis," she remarked. "At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important."
This research reinforces the goals of initiatives such as the "Start Genetic" campaign, which encourages healthcare providers to prioritize genetic screening in the initial diagnostic evaluation of neurodevelopmental delays. As the medical community moves toward a more personalized approach to autism care, the ability to accurately quantify the population of affected individuals will be essential for resource allocation, insurance coverage reform, and the successful execution of clinical trials.
The path forward requires a concerted effort to remove the economic and procedural barriers to genetic sequencing. As diagnostic technology becomes more accessible and less expensive, the burden of proof shifts to the healthcare system to ensure that these diagnostic tools are deployed equitably. For the thousands of families currently seeking answers, this study provides a new sense of urgency and a roadmap for identifying, supporting, and eventually treating a condition that is far more prevalent than the world previously understood.
